Cabozantinib (XL184) is a potent type II multi-tyrosine kinase (MET/VEGFR2/RET) inhibitor that binds to the inactive DFG-out conformation of the kinase domain. This binding suppresses MET, AKT, ERK, and STAT3 signaling pathways, effectively inhibiting tumor cell proliferation, migration, invasion, and angiogenesis.
Cabozantinib (XL184) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Cabozantinib (XL184) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.